Literature DB >> 10864889

Taurine blocks ATP-sensitive potassium channels of rat skeletal muscle fibres interfering with the sulphonylurea receptor.

D Tricarico1, M Barbieri, D C Camerino.   

Abstract

Taurine is a sulphonic aminoacid present in high amounts in various tissues including cardiac and skeletal muscles showing different properties such as antioxidative, antimyotonic and anti-schaemic effects. The cellular mechanism of action of taurine is under investigation and appears to involve the interaction of the sulphonic aminoacid with several ion channels. Using the patch-clamp technique we studied the effects of taurine in rat skeletal muscle fibres on ATP-sensitive K(+) channel (K(ATP)) immediately after excision and on channels that underwent rundown. The cytoplasmic application of 20 mM of taurine reduced the K(ATP) current; this effect was reverted by washout of the drug solution. In this experimental condition the IC(50) was 20.1 mM. After rundown, taurine inhibited the K(ATP) current with similar efficacy. Competition experiments showed that taurine shifted the dose-response inhibition curve of glybenclamide to the left on the log-dose axis without significantly affecting those of ATP or Ca(2+) ion. Single channel recording revealed that taurine affects the close state of the channel prolonging it and reducing the bursts duration. Our data indicate that taurine inhibits the muscular K(ATP) channel interfering with the glybenclamide site on the sulphonylurea receptor of the channel or on the site allosterically coupled to it. During ischaemia and hypoxia, the skeletal and heart muscles undergo several changes; for example, the activation of K(ATP) channels and loss of the intracellular taurine content. The depletion of taurine during ischaemia would contribute to the early activation of K(ATP) channels and salvage the intracellular ATP content.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864889      PMCID: PMC1572140          DOI: 10.1038/sj.bjp.0703385

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Alternative splicing of sur2 Exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel.

Authors:  W A Chutkow; J C Makielski; D J Nelson; C F Burant; Z Fan
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

2.  Interaction of taurine with the fast Na-current in isolated rabbit myocytes.

Authors:  O F Schanne; R Dumaine
Journal:  J Pharmacol Exp Ther       Date:  1992-12       Impact factor: 4.030

3.  Effects of pH upon the inhibition by sulphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle.

Authors:  I Findlay
Journal:  J Pharmacol Exp Ther       Date:  1992-07       Impact factor: 4.030

4.  KATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit.

Authors:  P Drain; L Li; J Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

5.  The effects of taurine on pharmacologically induced myotonia.

Authors:  D Conte Camerino; A De Luca; M Mambrini; E Ferrannini; F Franconi; A Giotti; S H Bryant
Journal:  Muscle Nerve       Date:  1989-11       Impact factor: 3.217

6.  The action of taurine on chloride conductance and excitability characteristics of rat striated muscle fibers.

Authors:  D Conte-Camerino; F Franconi; M Mambrini; F Bennardini; P Failli; S H Bryant; A Giotti
Journal:  Pharmacol Res Commun       Date:  1987-10

7.  Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.

Authors:  M Schwanstecher; C Sieverding; H Dörschner; I Gross; L Aguilar-Bryan; C Schwanstecher; J Bryan
Journal:  EMBO J       Date:  1998-10-01       Impact factor: 11.598

8.  Mechanisms of ischemia-induced taurine release in mouse hippocampal slices.

Authors:  P Saransaari; S S Oja
Journal:  Brain Res       Date:  1998-10-05       Impact factor: 3.252

9.  Effect of taurine on calcium paradox and ischemic heart failure.

Authors:  J H Kramer; J P Chovan; S W Schaffer
Journal:  Am J Physiol       Date:  1981-02

10.  Effects of mexiletine on ATP sensitive K+ channel of rat skeletal muscle fibres: a state dependent mechanism of action.

Authors:  D Tricarico; M Barbieri; C Franchini; V Tortorella; D C Camerino
Journal:  Br J Pharmacol       Date:  1998-10       Impact factor: 8.739

View more
  6 in total

1.  Taurine supplementation increases skeletal muscle force production and protects muscle function during and after high-frequency in vitro stimulation.

Authors:  Craig A Goodman; Deanna Horvath; Christos Stathis; Trevor Mori; Kevin Croft; Robyn M Murphy; Alan Hayes
Journal:  J Appl Physiol (1985)       Date:  2009-05-07

2.  Taurine regulates insulin release from pancreatic beta cell lines.

Authors:  William J L'Amoreaux; Christina Cuttitta; Allison Santora; Jonathan F Blaize; Janto Tachjadi; Abdeslem El Idrissi
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

Review 3.  Taurine: the appeal of a safe amino acid for skeletal muscle disorders.

Authors:  Annamaria De Luca; Sabata Pierno; Diana Conte Camerino
Journal:  J Transl Med       Date:  2015-07-25       Impact factor: 5.531

4.  Possible contribution of taurine to distorted glucagon secretion in intra-islet insulin deficiency: a metabolome analysis using a novel α-cell model of insulin-deficient diabetes.

Authors:  Megumi Bessho; Yuko Murase-Mishiba; Akihisa Imagawa; Jungo Terasaki; Toshiaki Hanafusa
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

Review 5.  Taurine and skeletal muscle disorders.

Authors:  Diana Conte Camerino; Domenico Tricarico; Sabata Pierno; Jean-François Desaphy; Antonella Liantonio; Michael Pusch; Rosa Burdi; Claudia Camerino; Bodvael Fraysse; Annamaria De Luca
Journal:  Neurochem Res       Date:  2004-01       Impact factor: 3.996

6.  Protective role of taurine against oxidative stress (Review).

Authors:  Stella Baliou; Maria Adamaki; Petros Ioannou; Aglaia Pappa; Mihalis I Panayiotidis; Demetrios A Spandidos; Ioannis Christodoulou; Anthony M Kyriakopoulos; Vassilis Zoumpourlis
Journal:  Mol Med Rep       Date:  2021-06-29       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.